Edition:
United Kingdom

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

33.19USD
19 Sep 2018
Change (% chg)

-- (--)
Prev Close
$33.19
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
274,046
52-wk High
$45.02
52-wk Low
$19.08

Latest Key Developments (Source: Significant Developments)

Editas Medicine Says Chief Medical Officer Will Step Down At End Of Year
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE ANNOUNCES TRANSITION OF CHIEF MEDICAL OFFICER.EDITAS MEDICINE - CHIEF MEDICAL OFFICER, GERALD COX WILL BE STEPPING DOWN AT END OF YEAR.  Full Article

Allergan And Editas Medicine Announce To Jointly Develop Crispr Genome Editing Experimental Medicine Edit-101
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Allergan plc ::ALLERGAN AND EDITAS MEDICINE ANNOUNCE EXERCISE OF OPTIONS TO JOINTLY DEVELOP CRISPR GENOME EDITING EXPERIMENTAL MEDICINE EDIT-101.EXERCISED OPTION TO DEVELOP & COMMERCIALIZE EDIT-101 GLOBALLY FOR TREATMENT OF LCA10.HAS PAID EDITAS MEDICINE A FEE OF $15 MILLION IN CONJUNCTION WITH EXERCISE OF ITS OPTION.ADDITIONALLY, EDITAS MEDICINE HAS EXERCISED ITS OPTION TO CO-DEVELOP, SHARE EQUALLY IN PROFITS AND LOSSES FROM EDIT-101 IN U.S..EDITAS MEDICINE ELIGIBLE TO RECEIVE ADDITIONAL $25 MILLION FROM ALLERGAN UPON ACCEPTANCE OF IND APPLICATION FOR EDIT-101 BY FDA.  Full Article

Editas Medicine Reports Data Demonstrating Subretinal Injection Of Edit-101 Well-Tolerated In Non-Human Primates
Friday, 18 May 2018 

Editas Medicine Inc ::EDITAS MEDICINE REPORTS DATA DEMONSTRATING SUBRETINAL INJECTION OF EDIT-101 WELL-TOLERATED IN NON-HUMAN PRIMATES.EDITAS MEDICINE INC - BOTH EDIT-101 AND VIR-067 WERE WELL TOLERATED IN ANIMALS TREATED WITH PROPHYLACTIC STEROIDS.EDITAS MEDICINE INC - EDITAS MEDICINE AIMS TO FILE AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR EDIT-101 BY MID-2018.  Full Article

Editas Medicine Reports Q1 Loss Per Share Of $0.67
Thursday, 3 May 2018 

May 3 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE ANNOUNCES FIRST QUARTER 2018 RESULTS AND UPDATE.Q1 LOSS PER SHARE $0.67.Q1 REVENUE $3.9 MILLION VERSUS I/B/E/S VIEW $4 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.82 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $359 MILLION AS OF MARCH 31, 2018.  Full Article

Editas Medicine Files For Potential Stock Shelf, Size Undisclosed - SEC Filing
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE INC FILES FOR POTENTIAL STOCK SHELF, SIZE UNDISCLOSED - SEC FILING.  Full Article

Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - ‍PRICING OF AN UNDERWRITTEN OFFERING OF 1.97 MILLION SHARES OF ITS COMMON STOCK​.  Full Article

Editas Medicine Announces Offering Of Common Stock
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Editas Medicine Inc ::EDITAS MEDICINE, INC., ANNOUNCES OFFERING OF COMMON STOCK.EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Editas Medicine announces Q3 loss per share $0.64
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Editas Medicine Inc ::Editas Medicine announces third quarter 2017 results and update.Q3 loss per share $0.64.Q3 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.Editas Medicine Inc - ‍cash, cash equivalents, and marketable securities at Sept. 30, 2017, were $295.7 million, compared to $199.9 million at Sept. 30, 2016​.  Full Article

Flagship Ventures Fund reports a 9.4 percent passive stake in Editas Medicine as of Dec 31, 2016
Monday, 13 Feb 2017 

Editas Medicine Inc :Flagship Ventures Fund reports a 9.4 percent passive stake in Editas Medicine Inc as of Dec 31, 2016 - SEC filing.  Full Article

UPDATE 2-U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing

Sept 10 A U.S. appeals court on Monday allowed a research center affiliated with the Massachusetts Institute of Technology and Harvard University to keep patents potentially worth billions of dollars on a groundbreaking gene editing technology known as CRISPR.